Keros Therapeutics, Inc. (KROS)
10.06
+0.06
(+0.55%)
USD |
NASDAQ |
Jun 09, 16:00
10.06
0.00 (0.00%)
After-Hours: 18:30
Keros Therapeutics SG&A Expense (Quarterly) : 10.15M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| PTC Therapeutics, Inc. | 86.18M |
| Insmed, Inc. | 247.26M |
| United Therapeutics Corp. | 156.60M |
| Enanta Pharmaceuticals, Inc. | 9.568M |
| ACADIA Pharmaceuticals, Inc. | 171.02M |